Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome.

Article Details

Citation
Copy to clipboard

Donn SM

Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome.

Expert Opin Investig Drugs. 2005 Mar;14(3):329-34.

PubMed ID
15833063 [ View in PubMed
]
Abstract

Lucinactant (Surfaxin, Discovery Laboratories) is a synthetic surfactant, which contains the novel peptide, sinapultide, a surfactant-associated protein B mimic. Randomised clinical trials suggest that this compound is a safe and effective treatment for respiratory distress syndrome in preterm infants. It is also being actively investigated for other indications, including meconium aspiration syndrome, treatment of bronchopulmonary dysplasia in neonates, acute respiratory distress syndrome and asthma. A novel aerosol formulation administered with nasal continuous positive airway pressure is also under development for treatment of respiratory insufficiency in neonates. Its non-animal origin may make it an attractive alternative to present animal-derived surfactants by eliminating the risks of infection and immunogenicity related to the latter.

DrugBank Data that Cites this Article

Drugs